marketcaparena
Search

    AYTU

    AYTU BIOPHARMA, INC

    Company overview

    Market capitalization
    $23.58M
    Employees
    82
    Latest publication
    2026-09-29
    About AYTU BIOPHARMA, INC

    Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

    Company website

    Financial statements

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-06-30 · USDFY 20252025-06-30 · USDFY 20242024-06-30 · USDFY 20232023-06-30 · USDFY 20222022-06-30 · USDFY 20212021-06-30 · USDFY 20202020-06-30 · USDFY 20192019-06-30 · USD
    Total Revenue57,570,000USD66,382,000USD65,183,000USD107,399,000USD96,669,000USD65,632,000USD27,632,000USD7,320,357USD
    Cost Of Revenue20,752,000USD20,551,000USD16,129,000USD40,767,000USD46,386,000USD36,432,000USD8,281,000USD2,202,041USD
    Gross Profit36,818,000USD45,831,000USD49,054,000USD66,632,000USD50,283,000USD29,200,000USD19,351,000USD5,118,316USD
    Research Development0USD1,326,000USD2,769,000USD4,095,000USD12,662,000USD5,623,000USD1,722,000USD589,072USD
    Selling General Administrative19,272,000USD17,379,000USD19,954,000USD28,630,000USD31,167,000USD25,500,000USD19,657,000USD19,239,626USD
    Selling And Marketing Expenses23,369,000USD20,906,000USD22,083,000USD41,448,000USD38,713,000USD30,308,000USD11,403,000USD—
    General And Administrative Expenses19,272,000USD———————
    Total Operating Expenses45,133,000USD53,658,000USD50,645,000USD83,697,000USD160,189,000USD88,070,000USD40,482,000USD21,964,953USD
    Operating Income-8,315,000USD-7,827,000USD-1,591,000USD-17,065,000USD-109,906,000USD-58,870,000USD-21,131,000USD-16,846,637USD
    Total Other Income Expense Net-5,916,000USD-5,918,000USD-8,787,000USD14,000USD1,017,000USD840,000USD7,510,000USD-10,285,271USD
    Interest Expense1,895,000USD3,703,000USD4,792,000USD4,963,000USD147,498,000USD37,530,000USD0USD0USD
    Income Before Tax-14,231,000USD-13,745,000USD-10,378,000USD-17,051,000USD-108,889,000USD-58,030,000USD-13,621,000USD-27,131,908USD
    Income Tax Expense21,000USD437,000USD2,142,000USD-57,000USD-110,000USD259,000USD-9,921,076USD20,035,042USD
    Discontinued Operations0USD———————
    Net Income-14,252,000USD-13,562,000USD-15,844,000USD-17,051,000USD-108,779,000USD-58,289,000USD-13,621,000USD-47,166,950USD
    Unclassified Operating Expenses—14,047,000USD5,839,000USD9,524,000USD77,647,000USD26,639,000USD7,700,000USD2,136,255USD
    Net Interest Income—-3,703,000USD-4,792,000USD-4,963,000USD————
    Tax Provision—437,000USD1,768,000USD0USD-110,000USD259,000USD0USD—
    Net Income From Continuing Ops—-14,182,000USD-15,844,000USD-17,051,000USD-110,173,000USD-58,289,000USD-13,620,679USD-27,131,908USD
    Ebit—-10,042,000USD-5,319,000USD-12,088,000USD-38,103,000USD-38,240,000USD-17,921,000USD-16,846,637USD
    Ebitda—-4,665,000USD1,406,000USD-3,273,000USD-27,957,000USD-29,039,000USD-12,207,000USD-14,610,382USD
    Depreciation And Amortization—5,377,000USD6,725,000USD8,815,000USD10,146,000USD9,201,000USD5,714,000USD2,236,255USD
    Reconciled Depreciation—5,377,000USD8,272,000USD4,788,000USD10,251,000USD9,201,000USD6,245,827USD2,727,067USD
    Net Income Applicable To Common Shares———-17,051,000USD-110,173,000USD-58,289,000USD-13,620,679USD-27,131,908USD
    Non Operating Income Net Other——————10,116,354USD-9,749,771USD
    Interest Income———————454,720USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-03-31 · USDQ2 20262025-12-31 · USDQ1 20262025-09-30 · USDQ4 20252025-06-30 · USDQ3 20252025-03-31 · USDQ2 20252024-12-31 · USDQ1 20252024-09-30 · USDQ4 20242024-06-30 · USD
    Total Revenue12,411,000USD15,165,000USD13,888,000USD15,135,000USD18,452,000USD16,221,000USD16,574,000USD17,976,000USD
    Cost Of Revenue5,573,000USD6,067,000USD4,702,000USD4,881,000USD5,646,000USD5,435,000USD4,589,000USD6,070,000USD
    Gross Profit6,838,000USD9,098,000USD9,186,000USD10,254,000USD12,806,000USD10,786,000USD11,985,000USD11,906,000USD
    Research Development0USD0USD0USD216,000USD162,000USD522,000USD426,000USD1,044,000USD
    Selling General Administrative4,973,000USD5,070,000USD4,924,000USD3,696,000USD4,109,000USD4,449,000USD5,125,000USD4,677,000USD
    Selling And Marketing Expenses5,929,000USD5,998,000USD5,322,000USD4,781,000USD5,194,000USD5,272,000USD5,659,000USD6,411,000USD
    Total Operating Expenses10,902,000USD11,068,000USD10,690,000USD17,877,000USD10,385,000USD12,481,000USD12,915,000USD15,556,000USD
    Operating Income-4,064,000USD-1,970,000USD-1,504,000USD-7,623,000USD2,421,000USD-1,695,000USD-930,000USD-3,650,000USD
    Interest Expense436,000USD560,000USD516,000USD730,000USD900,000USD1,079,000USD994,000USD4,792,000USD
    Net Interest Income-436,000USD-560,000USD-516,000USD-730,000USD-900,000USD-1,079,000USD-994,000USD—
    Income Before Tax-5,608,000USD-10,584,000USD1,965,000USD-19,443,000USD3,818,000USD382,000USD1,498,000USD-3,922,000USD
    Income Tax Expense10,000USD——437,000USD-122,000USD-283,000USD405,000USD695,000USD
    Tax Provision10,000USD0USD0USD437,000USD-122,000USD-283,000USD405,000USD695,000USD
    Net Income-5,618,000USD-10,584,000USD1,965,000USD-19,818,000USD3,994,000USD788,000USD1,474,000USD-4,617,000USD
    Net Income From Continuing Ops-5,618,000USD-10,584,000USD1,965,000USD-19,880,000USD3,940,000USD665,000USD1,093,000USD-4,617,000USD
    Ebit-4,064,000USD-10,024,000USD2,481,000USD-18,713,000USD4,718,000USD1,461,000USD2,492,000USD-7,924,000USD
    Ebitda-2,943,000USD-9,139,000USD3,284,000USD-17,419,000USD6,035,000USD2,634,000USD3,919,000USD-5,980,000USD
    Depreciation And Amortization1,121,000USD885,000USD803,000USD1,294,000USD1,317,000USD1,173,000USD1,427,000USD1,944,000USD
    Reconciled Depreciation1,121,000USD885,000USD803,000USD1,294,000USD1,483,000USD1,173,000USD1,427,000USD1,944,000USD
    Total Other Income Expense Net-1,544,000USD-8,614,000USD3,469,000USD-11,820,000USD1,397,000USD2,077,000USD2,428,000USD-272,000USD
    Unclassified Operating Expenses———9,184,000USD—2,238,000USD1,705,000USD3,424,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ4 20262026-06-30 · USDQ3 20262026-03-31 · USDQ2 20262025-12-31 · USDQ1 20262025-09-30 · USDQ4 20252025-06-30 · USDQ3 20252025-03-31 · USDQ2 20252024-12-31 · USDQ1 20252024-09-30 · USD
    Total Assets105,007,000USD111,689,000USD122,000,000USD124,988,000USD124,177,000USD124,201,000USD116,227,000USD115,831,000USD
    Cash And Equivalents26,308,000USD———————
    Total Current Assets61,761,000USD67,326,000USD76,241,000USD81,109,000USD79,179,000USD72,512,000USD63,053,000USD60,738,000USD
    Other Current Assets5,814,000USD8,662,000USD6,637,000USD5,154,000USD5,638,000USD7,456,000USD6,167,000USD5,732,000USD
    Other Non Current Assets601,000USD———————
    Total Liabilities69,733,000USD———————
    Total Current Liabilities54,659,000USD59,972,000USD65,563,000USD65,993,000USD63,064,000USD70,706,000USD64,048,000USD61,252,000USD
    Other Current Liabilities239,000USD———————
    Other Non Current Liabilities4,774,000USD———————
    Total Stockholder Equity35,274,000USD35,143,000USD14,201,000USD23,171,000USD18,966,000USD34,898,000USD30,765,000USD29,826,000USD
    Total Equity Including Noncontrolling Interest35,274,000USD———————
    Short Long Term Debt1,857,000USD12,268,000USD10,932,000USD16,730,000USD10,920,000USD11,885,000USD5,869,000USD6,127,000USD
    Long Term Debt9,101,000USD9,549,000USD9,998,000USD10,447,000USD10,895,000USD9,535,000USD9,983,000USD10,430,000USD
    Net Receivables22,779,000USD24,489,000USD30,923,000USD33,225,000USD31,155,000USD35,825,000USD25,403,000USD23,159,000USD
    Inventory6,860,000USD7,460,000USD8,656,000USD10,100,000USD11,434,000USD11,058,000USD11,085,000USD11,739,000USD
    Property Plant Equipment Net1,242,000USD1,317,000USD1,443,000USD1,510,000USD1,593,000USD1,657,000USD1,694,000USD1,917,000USD
    Intangible Assets41,403,000USD42,490,000USD43,578,000USD41,430,000USD42,201,000USD48,711,000USD49,958,000USD51,205,000USD
    Accounts Payable11,284,000USD13,214,000USD14,259,000USD12,342,000USD10,601,000USD12,041,000USD11,699,000USD13,513,000USD
    Short Term Debt221,000USD12,470,000USD11,130,000USD16,730,000USD11,057,000USD11,987,000USD6,051,000USD6,611,000USD
    Common Stock1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD
    Retained Earnings-347,787,000USD-347,772,000USD-342,154,000USD-331,570,000USD-333,535,000USD-313,717,000USD-317,711,000USD-318,499,000USD
    Total Liab—76,546,000USD107,799,000USD101,817,000USD105,211,000USD89,303,000USD85,462,000USD86,005,000USD
    Other Current Liab—34,288,000USD40,174,000USD36,921,000USD41,406,000USD46,678,000USD46,298,000USD41,128,000USD
    Capital Stock—1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD
    Cash—26,715,000USD30,025,000USD32,630,000USD30,952,000USD18,173,000USD20,398,000USD20,108,000USD
    Cash And Short Term Investments—26,715,000USD30,025,000USD32,630,000USD30,952,000USD18,173,000USD20,398,000USD20,108,000USD
    Net Debt—-3,777,000USD-6,951,000USD-5,453,000USD-8,015,000USD4,349,999USD-3,258,000USD-1,923,000USD
    Short Long Term Debt Total—22,938,000USD23,074,000USD27,177,000USD22,937,000USD22,522,999USD17,140,000USD18,185,000USD
    Property Plant Equipment Gross—2,119,000USD2,211,000USD2,245,000USD2,307,000USD2,347,000USD2,345,000USD3,782,000USD
    Common Stock Shares Outstanding—10,511,583shares10,036,359shares19,476,635shares6,791,532shares8,204,453shares8,485,112shares9,099,601shares
    Non Current Assets Total—44,363,000USD45,759,000USD43,879,000USD44,998,000USD51,689,000USD53,174,000USD55,093,000USD
    Non Current Liabilities Total—16,574,000USD42,236,000USD35,824,000USD42,147,000USD18,597,000USD21,414,000USD24,753,000USD
    Non Current Liabilities Other—4,843,000USD4,901,000USD4,953,000USD4,918,000USD4,937,000USD5,045,000USD4,921,000USD
    Non Currrent Assets Other—556,000USD738,000USD939,000USD1,204,000USD1,321,000USD1,522,000USD1,971,000USD
    Net Working Capital—7,354,000USD10,678,000USD15,116,000USD16,115,000USD1,806,000USD-995,000USD-514,000USD
    Unclassified Current Liabilities—-12,268,000USD-10,932,000USD-16,730,000USD-10,920,000USD-11,885,000USD-5,869,000USD-6,127,000USD
    Unclassified Non Current Liabilities—2,182,000USD27,337,000USD20,424,000USD26,334,000USD4,125,000USD6,386,000USD9,402,000USD
    Unclassified Equity—382,913,000USD356,353,000USD354,739,000USD352,499,000USD348,613,000USD348,474,000USD348,323,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-06-30 · USDFY 20252025-06-30 · USDFY 20242024-06-30 · USDFY 20232023-06-30 · USDFY 20222022-06-30 · USDFY 20212021-06-30 · USDFY 20202020-06-30 · USDFY 20192019-06-30 · USD
    Total Assets105,007,000USD124,177,000USD118,857,000USD137,841,000USD137,623,000USD265,668,000USD152,836,330USD34,721,391USD
    Cash And Equivalents26,308,000USD———————
    Total Current Assets61,761,000USD79,179,000USD61,891,000USD72,832,000USD59,929,000USD105,234,000USD74,965,772USD15,432,864USD
    Other Current Assets5,814,000USD5,638,000USD6,218,000USD8,914,999USD8,008,000USD11,070,000USD5,742,011USD1,207,781USD
    Other Non Current Assets601,000USD———————
    Total Liabilities69,733,000USD———————
    Total Current Liabilities54,659,000USD63,064,000USD62,228,000USD69,015,000USD64,441,999USD109,438,000USD28,306,581USD5,372,576USD
    Other Current Liabilities239,000USD———————
    Other Non Current Liabilities4,774,000USD———————
    Total Stockholder Equity35,274,000USD18,966,000USD27,716,000USD39,357,000USD44,308,000USD137,568,000USD95,015,296USD7,087,818USD
    Total Equity Including Noncontrolling Interest35,274,000USD———————
    Short Long Term Debt1,857,000USD10,920,000USD4,252,000USD1,648,000USD3,909,000USD24,602,000USD1,492,076USD—
    Long Term Debt9,101,000USD10,895,000USD10,877,000USD14,713,000USD14,279,000USD180,000USD11,171,491USD—
    Net Receivables22,779,000USD31,155,000USD23,526,000USD28,937,000USD21,712,000USD28,176,000USD5,175,924USD1,740,787USD
    Inventory6,860,000USD11,434,000USD12,141,000USD11,995,000USD10,849,000USD16,339,000USD9,999,441USD1,440,069USD
    Property Plant Equipment Net1,242,000USD1,593,000USD1,522,000USD3,869,000USD6,296,000USD8,703,000USD892,609USD203,733USD
    Intangible Assets41,403,000USD42,201,000USD52,453,000USD58,970,000USD70,632,000USD85,464,000USD48,854,561USD19,082,594USD
    Accounts Payable11,284,000USD10,601,000USD10,314,000USD13,478,000USD10,987,000USD19,255,000USD11,824,560USD2,133,522USD
    Short Term Debt221,000USD11,057,000USD4,964,000USD8,738,000USD3,909,000USD25,542,000USD1,282,502USD—
    Common Stock1,000USD1,000USD1,000USD1,000USD4,000USD3,000USD12,584USD1,754USD
    Retained Earnings-347,787,000USD-333,535,000USD-319,973,000USD-304,129,000USD-287,078,000USD-178,299,000USD-120,010,179USD-106,389,500USD
    Total Liab—105,211,000USD91,141,000USD98,484,000USD93,315,000USD128,100,000USD57,821,034USD27,633,573USD
    Other Current Liab—41,406,000USD46,950,000USD46,799,000USD49,545,999USD7,407,000USD14,860,183USD3,239,054USD
    Capital Stock—1,000USD1,000USD1,000USD4,000USD3,000USD12,584USD2,113USD
    Cash—30,952,000USD20,006,000USD22,985,000USD19,360,000USD49,649,000USD48,081,715USD11,044,227USD
    Cash And Short Term Investments—30,952,000USD20,006,000USD22,985,000USD19,360,000USD49,649,000USD48,081,715USD11,044,227USD
    Net Debt—-8,015,000USD-3,588,000USD7,441,000USD-1,172,000USD-18,679,000USD-46,073,839USD-11,044,227USD
    Short Long Term Debt Total—22,937,000USD16,418,000USD30,426,000USD18,188,000USD30,970,000USD12,453,993USD—
    Property Plant Equipment Gross—2,307,000USD3,647,000USD3,869,000USD6,296,000USD8,703,000USD1,151,609USD204,000USD
    Common Stock Shares Outstanding—6,279,744shares5,537,957shares3,339,906shares1,470,000shares840,000shares225,960shares38,972shares
    Non Current Assets Total—44,998,000USD56,966,000USD65,009,000USD77,694,000USD160,434,000USD77,870,558USD19,288,527USD
    Non Current Liabilities Total—42,147,000USD28,913,000USD29,468,999USD28,873,001USD18,662,000USD29,514,453USD22,260,997USD
    Non Current Liabilities Other—4,918,000USD4,529,000USD6,975,000USD12,810,000USD15,858,000USD18,331,591USD22,247,796USD
    Non Currrent Assets Other—1,204,000USD2,229,000USD792,000USD766,000USD465,000USD32,981USD2,200USD
    Net Working Capital—16,115,000USD-337,000USD3,817,000USD-4,513,000USD-4,204,000USD46,659,191USD10,060,288USD
    Unclassified Current Liabilities—-10,920,000USD-42,826,000USD-48,447,000USD-61,143,000USD-24,602,000USD-1,492,076USD—
    Unclassified Non Current Liabilities—26,334,000USD13,507,000USD-5,597,001USD-11,025,999USD-13,234,000USD-28,789,079USD-22,260,997USD
    Unclassified Equity—352,499,000USD347,687,000USD343,484,000USD331,378,000USD315,861,000USD215,484,307USD113,869,451USD
    Current Deferred Revenue——38,574,000USD46,799,000USD57,234,000USD57,234,000USD339,336USD—
    Other Liab———13,378,000USD12,810,000USD15,858,000USD28,789,079USD22,260,997USD
    Other Assets———792,000USD766,000USD465,000USD32,981USD2,200USD
    Net Tangible Assets———-19,613,000USD-24,540,000USD-13,698,000USD34,657,175USD-11,995,135USD
    Good Will————65,802,000USD65,802,000USD28,090,407USD—
    Accumulated Other Comprehensive Income————0USD0USD-484,000USD-396,000USD
    Unclassified Non Current Assets————-66,568,000USD———
    Deferred Long Term Liab——————11,371USD13,201USD
    Unclassified Current Assets——————5,966,681USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-06-30 · USDFY 20252025-06-30 · USDFY 20242024-06-30 · USDFY 20232023-06-30 · USDFY 20222022-06-30 · USDFY 20212021-06-30 · USDFY 20202020-06-30 · USDFY 20192019-06-30 · USD
    Depreciation2,592,000USD5,377,000USD6,725,000USD8,815,000USD10,146,000USD9,201,000USD6,245,827USD2,727,067USD
    Stock Based Compensation691,000USD576,000USD2,373,000USD6,046,000USD5,248,000USD3,574,000USD1,079,000USD1,022,202USD
    Other Non Cash Items-44,000USD11,405,000USD10,018,000USD2,860,000USD75,425,000USD17,869,000USD-10,041,661USD9,842,240USD
    Change To Account Receivables8,376,000USD-7,629,000USD5,201,000USD-7,153,000USD6,533,000USD1,544,000USD-3,560,860USD-1,162,005USD
    Change To Inventory2,387,000USD382,000USD-4,821,000USD-3,609,000USD1,299,000USD2,786,000USD-6,950,624USD-101,096USD
    Change To Liabilities-5,449,000USD——2,384,000USD-7,681,000USD-3,245,000USD4,078,959USD1,570,674USD
    Change In Working Capital8,270,000USD-5,733,000USD-4,660,000USD-5,799,000USD-10,863,000USD1,681,000USD-12,609,902USD-210,199USD
    Operating Cash Flow3,281,000USD———————
    Capital Expenditures-29,000USD-3,228,000USD-329,000USD0USD-2,341,000USD-2,341,000USD-5,850,000USD-59,848USD
    Other Investing Activities0USD———————
    Investing Cash Flow-29,000USD———————
    Net Debt Issuance-1,857,000USD———————
    Unclassified Financing Cash Flow-6,039,000USD————-4,903,000USD-21,587,739USD-30,735,026USD
    Financing Cash Flow-7,896,000USD———————
    Change In Cash-4,644,000USD10,946,000USD-2,979,000USD3,625,000USD-30,541,000USD1,568,000USD37,039,080USD4,181,700USD
    End Cash Flow26,308,000USD———————
    Net Income—-13,562,000USD-15,844,000USD-17,051,000USD-108,779,000USD-58,289,000USD-13,620,679USD-27,131,908USD
    Total Cash From Operating Activities—-1,937,000USD-1,388,000USD-5,129,000USD-28,823,000USD-25,964,000USD-28,373,887USD-13,831,377USD
    Free Cash Flow—-5,165,000USD-1,717,000USD-5,129,000USD-28,823,000USD-25,964,000USD-28,373,887USD-13,891,225USD
    Investments—-2,560,000USD-329,000USD-117,000USD-3,248,000USD-2,782,000USD-5,655,772USD-1,061,985USD
    Total Cashflows From Investing Activities—-2,560,000USD-329,000USD-117,000USD-3,248,000USD-2,782,000USD-5,655,772USD-1,061,985USD
    Net Borrowings—6,668,000USD-1,890,000USD-2,346,000USD-5,222,000USD-3,741,000USD-16,248,851USD5,000,000USD
    Total Cash From Financing Activities—15,443,000USD-1,262,000USD8,871,000USD1,530,000USD30,314,000USD71,068,739USD19,075,062USD
    Issuance Of Capital Stock—14,840,000USD3,467,000USD15,575,000USD11,694,000USD45,051,000USD65,729,900USD15,180,000USD
    Begin Period Cash Flow—20,006,000USD22,985,000USD19,360,000USD49,901,000USD48,333,000USD11,294,227USD7,112,527USD
    End Period Cash Flow—30,952,000USD20,006,000USD22,985,000USD19,360,000USD49,901,000USD48,333,307USD11,294,227USD
    Other Cashflows From Investing Activities—-2,332,000USD-329,000USD-112,000USD-70,000USD-2,301,000USD-5,844,000USD-497,112USD
    Other Cashflows From Financing Activities—-6,065,000USD-2,839,000USD-4,358,000USD-4,942,000USD-6,093,000USD21,587,739USD29,255,062USD
    Unclassified Investing Cash Flow—5,560,000USD——2,411,000USD4,642,000USD11,694,000USD—
    Sale Purchase Of Stock——————87,317,590USD15,555,026USD
    Cash And Cash Equivalents Changes——————37,039,080USD4,181,700USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-03-31 · USDQ2 20262025-12-31 · USDQ1 20262025-09-30 · USDQ4 20252025-06-30 · USDQ3 20252025-03-31 · USDQ2 20252024-12-31 · USDQ1 20252024-09-30 · USDQ4 20242024-06-30 · USD
    Net Income-5,618,000USD-10,584,000USD1,965,000USD-19,880,000USD3,994,000USD788,000USD1,474,000USD-4,617,000USD
    Depreciation1,121,000USD885,000USD803,000USD1,294,000USD1,483,000USD1,173,000USD1,427,000USD1,692,000USD
    Stock Based Compensation148,000USD283,000USD114,000USD113,000USD139,000USD151,000USD173,000USD242,000USD
    Other Non Cash Items2,129,000USD9,108,000USD-3,477,000USD19,748,000USD-2,313,000USD-2,445,000USD-3,410,000USD3,465,999USD
    Change To Account Receivables6,434,000USD2,301,999USD-2,069,999USD4,670,000USD-10,505,000USD-2,272,000USD478,000USD5,732,000USD
    Change To Inventory543,000USD609,000USD1,056,000USD-518,000USD-61,000USD627,000USD334,000USD-2,009,999USD
    Change In Working Capital-1,814,000USD3,983,000USD-23,000USD1,641,000USD-9,758,000USD3,238,000USD-854,000USD-1,570,999USD
    Total Cash From Operating Activities-4,182,000USD3,675,000USD-618,000USD2,803,000USD-6,455,000USD2,905,000USD-1,190,000USD-788,000USD
    Capital Expenditures0USD-17,000USD0USD-17,000USD-69,000USD-6,000USD-136,000USD-329,000USD
    Free Cash Flow-4,182,000USD3,658,000USD-618,000USD2,786,000USD-6,524,000USD2,899,000USD-1,326,000USD-1,117,000USD
    Net Borrowings872,000USD-6,263,000USD5,346,000USD428,000USD5,552,000USD-723,000USD1,411,000USD—
    Total Cash From Financing Activities872,000USD-6,263,000USD2,296,000USD12,993,000USD4,299,000USD-2,760,000USD911,000USD1,068,000USD
    Change In Cash-3,310,000USD-2,605,000USD1,678,000USD12,779,000USD-2,225,000USD290,000USD102,000USD246,000USD
    Begin Period Cash Flow30,025,000USD32,630,000USD30,952,000USD18,173,000USD20,398,000USD20,108,000USD20,006,000USD19,760,000USD
    End Period Cash Flow26,715,000USD30,025,000USD32,630,000USD30,952,000USD18,173,000USD20,398,000USD20,108,000USD20,006,000USD
    Other Cashflows From Financing Activities872,000USD—2,296,000USD—-1,253,000USD-2,037,000USD-500,000USD16,720,000USD
    Total Cashflows From Investing Activities—-17,000USD—-3,017,000USD-69,000USD145,000USD381,000USD-34,000USD
    Investments——0USD-3,017,000USD-69,000USD145,000USD381,000USD-34,000USD
    Unclassified Financing Cash Flow——-5,346,000USD-2,275,000USD———-19,033,000USD
    Issuance Of Capital Stock———14,840,000USD0USD——3,381,000USD
    Other Cashflows From Investing Activities—————151,000USD517,000USD295,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    FY 2024Yearly · 2024-06-30GeographyInternational91,000USD0001437749-24-030062
    FY 2024Yearly · 2024-06-30GeographyUnited States80,911,000USD0001437749-24-030062
    FY 2024Yearly · 2024-06-30SegmentConsumer Health15,819,000USD0001437749-24-030062
    FY 2024Yearly · 2024-06-30SegmentRx65,183,000USD0001437749-24-030062
    Q4 2024Quarterly · 2024-06-30SegmentConsumer Health3,383,000USD0001437749-24-030062
    Q4 2024Quarterly · 2024-06-30SegmentRx14,593,000USD0001437749-24-030062
    Q3 2024Quarterly · 2024-03-31SegmentConsumer Health3,968,000USD0001437749-24-017051
    Q3 2024Quarterly · 2024-03-31SegmentRx14,025,000USD0001437749-24-017051
    Q2 2024Quarterly · 2023-12-31SegmentConsumer Health4,186,000USD0001437749-24-004149
    Q2 2024Quarterly · 2023-12-31SegmentRx18,748,000USD0001437749-24-004149
    Q1 2024Quarterly · 2023-09-30SegmentConsumer Health4,282,000USD0001558370-23-019015
    Q1 2024Quarterly · 2023-09-30SegmentRx17,817,000USD0001558370-23-019015
    Q1 2024Quarterly · 2023-09-30ProductAttention Deficit Hyperactivity Disorder Portfolio15,128,000USD0001558370-23-019015
    Q1 2024Quarterly · 2023-09-30ProductManufactured Product Other4,406,000USD0001558370-23-019015
    Q1 2024Quarterly · 2023-09-30ProductPediatric Portfolio2,565,000USD0001558370-23-019015
    FY 2023Yearly · 2023-06-30GeographyInternational481,000USD0001437749-24-030062
    FY 2023Yearly · 2023-06-30GeographyUnited States106,918,000USD0001437749-24-030062
    FY 2023Yearly · 2023-06-30SegmentConsumer Health33,600,000USD0001437749-24-030062
    FY 2023Yearly · 2023-06-30SegmentRx73,799,000USD0001437749-24-030062
    Q4 2023Quarterly · 2023-06-30SegmentConsumer Health7,419,000USDLegacy provider
    Q4 2023Quarterly · 2023-06-30SegmentRx23,313,000USDLegacy provider
    Q3 2023Quarterly · 2023-03-31SegmentConsumer Health8,928,000USD0001437749-24-017051
    Q3 2023Quarterly · 2023-03-31SegmentRx13,805,000USD0001437749-24-017051
    Q2 2023Quarterly · 2022-12-31SegmentConsumer Health8,250,000USD0001437749-24-004149
    Q2 2023Quarterly · 2022-12-31SegmentRx18,029,000USD0001437749-24-004149
    Q1 2023Quarterly · 2022-09-30SegmentConsumer Health9,003,000USD0001558370-23-019015
    Q1 2023Quarterly · 2022-09-30SegmentRx18,652,000USD0001558370-23-019015
    Q1 2023Quarterly · 2022-09-30ProductAttention Deficit Hyperactivity Disorder Portfolio11,585,000USD0001558370-22-017751
    Q1 2023Quarterly · 2022-09-30ProductConsumer Health Portfolio9,003,000USD0001558370-22-017751
    Q1 2023Quarterly · 2022-09-30ProductOther Product Portfolio509,000USD0001558370-22-017751
    Q1 2023Quarterly · 2022-09-30ProductPediatric Portfolio6,558,000USD0001558370-22-017751
    Q1 2023Quarterly · 2022-09-30GeographyInternational179,000USD0001558370-22-017751
    Q1 2023Quarterly · 2022-09-30GeographyUnited States27,476,000USD0001558370-22-017751
    FY 2022Yearly · 2022-06-30GeographyInternational2,063,000USD0001558370-23-016393
    FY 2022Yearly · 2022-06-30GeographyUnited States94,606,000USD0001558370-23-016393
    FY 2022Yearly · 2022-06-30SegmentConsumer Health35,548,000USD0001558370-23-016393
    FY 2022Yearly · 2022-06-30SegmentRx61,121,000USD0001558370-23-016393
    Q4 2022Quarterly · 2022-06-30GeographyInternational250,000USDLegacy provider
    Q4 2022Quarterly · 2022-06-30GeographyUnited States27,198,000USDLegacy provider
    FY 2022Yearly · 2022-06-30ProductAttention Deficit Hyperactivity Disorder Portfolio42,855,000USD0001558370-22-014652
    FY 2022Yearly · 2022-06-30ProductConsumer Health Portfolio35,548,000USD0001558370-22-014652
    FY 2022Yearly · 2022-06-30ProductOther Product Portfolio2,182,000USD0001558370-22-014652
    FY 2022Yearly · 2022-06-30ProductPediatric Portfolio16,084,000USD0001558370-22-014652
    Q3 2022Quarterly · 2022-03-31ProductConsumer Health Portfolio10,337,000USD0001558370-22-008952
    Q3 2022Quarterly · 2022-03-31ProductPediatric Portfolio13,590,000USD0001558370-22-008952
    Q3 2022Quarterly · 2022-03-31ProductPrimary Care Portfolio272,000USD0001558370-22-008952
    Q3 2022Quarterly · 2022-03-31GeographyInternational444,000USD0001558370-22-008952
    Q3 2022Quarterly · 2022-03-31GeographyUnited States23,755,000USD0001558370-22-008952
    Q2 2022Quarterly · 2021-12-31ProductConsumer Health Portfolio8,482,000USD0001558370-22-001110
    Q2 2022Quarterly · 2021-12-31ProductPediatric Portfolio14,451,000USD0001558370-22-001110
    Q2 2022Quarterly · 2021-12-31ProductPrimary Care Portfolio192,000USD0001558370-22-001110
    Q2 2022Quarterly · 2021-12-31GeographyInternational578,000USD0001558370-22-001110
    Q2 2022Quarterly · 2021-12-31GeographyUnited States22,547,000USD0001558370-22-001110
    Q1 2022Quarterly · 2021-09-30ProductAttention Deficit Hyperactivity Disorder Portfolio9,327,000USD0001558370-22-017751
    Q1 2022Quarterly · 2021-09-30ProductConsumer Health Portfolio8,014,000USD0001558370-22-017751
    Q1 2022Quarterly · 2021-09-30ProductOther Product Portfolio758,000USD0001558370-22-017751
    Q1 2022Quarterly · 2021-09-30ProductPediatric Portfolio3,798,000USD0001558370-22-017751
    Q1 2022Quarterly · 2021-09-30GeographyInternational791,000USD0001558370-22-017751
    Q1 2022Quarterly · 2021-09-30GeographyUnited States21,106,000USD0001558370-22-017751
    FY 2021Yearly · 2021-06-30GeographyInternational4,945,000USD0001558370-22-014652
    FY 2021Yearly · 2021-06-30GeographyUnited States60,687,000USD0001558370-22-014652
    FY 2021Yearly · 2021-06-30SegmentBiopharma32,678,000USD0001558370-22-014652
    FY 2021Yearly · 2021-06-30SegmentConsumer Health32,954,000USD0001558370-22-014652
    Q4 2021Quarterly · 2021-06-30GeographyInternational1,040,000USDLegacy provider
    Q4 2021Quarterly · 2021-06-30GeographyUnited States22,442,000USDLegacy provider
    FY 2021Yearly · 2021-06-30ProductAttention Deficit Hyperactivity Disorder Portfolio10,883,000USD0001558370-22-014652
    FY 2021Yearly · 2021-06-30ProductConsumer Health Portfolio32,954,000USD0001558370-22-014652
    FY 2021Yearly · 2021-06-30ProductOther Product Portfolio9,358,000USD0001558370-22-014652
    FY 2021Yearly · 2021-06-30ProductPediatric Portfolio12,437,000USD0001558370-22-014652
    Q3 2021Quarterly · 2021-03-31ProductConsumer Health Portfolio8,356,000USD0001558370-22-008952
    Q3 2021Quarterly · 2021-03-31ProductPediatric Portfolio3,918,000USD0001558370-22-008952
    Q3 2021Quarterly · 2021-03-31ProductPrimary Care Portfolio1,209,000USD0001558370-22-008952
    Q3 2021Quarterly · 2021-03-31GeographyInternational1,139,000USD0001558370-22-008952
    Q3 2021Quarterly · 2021-03-31GeographyUnited States12,344,000USD0001558370-22-008952
    Q2 2021Quarterly · 2020-12-31ProductConsumer Health Portfolio7,935,000USD0001558370-22-001110
    Q2 2021Quarterly · 2020-12-31ProductPediatric Portfolio3,115,000USD0001558370-22-001110
    Q2 2021Quarterly · 2020-12-31ProductPrimary Care Portfolio4,097,000USD0001558370-22-001110
    Q2 2021Quarterly · 2020-12-31GeographyInternational1,390,000USD0001558370-22-001110
    Q2 2021Quarterly · 2020-12-31GeographyUnited States13,757,000USD0001558370-22-001110
    Q1 2021Quarterly · 2020-09-30ProductConsumer Health Portfolio7,768,000USD0001558370-21-015996
    Q1 2021Quarterly · 2020-09-30ProductPediatric Portfolio2,719,000USD0001558370-21-015996
    Q1 2021Quarterly · 2020-09-30ProductPrimary Care And Devices Legacy3,033,000USD0001558370-21-015996
    FY 2020Yearly · 2020-06-30GeographyInternational2,652,000USD0001558370-21-012825
    FY 2020Yearly · 2020-06-30GeographyUnited States24,980,000USD0001558370-21-012825
    FY 2020Yearly · 2020-06-30SegmentAytu Bio Pharma17,249,000USD0001558370-21-012825
    FY 2020Yearly · 2020-06-30SegmentAytu Consumer Health10,383,000USD0001558370-21-012825
    FY 2020Yearly · 2020-06-30ProductConsumer Health Portfolio10,383,000USD0001558370-21-012825
    FY 2020Yearly · 2020-06-30ProductPediatric Portfolio9,292,000USD0001558370-21-012825
    FY 2020Yearly · 2020-06-30ProductPrimary Care And Devices Legacy7,957,000USD0001558370-21-012825
    FY 2019Yearly · 2019-06-30GeographyRow858,000USD0001654954-20-010891
    FY 2019Yearly · 2019-06-30GeographyUnited States6,462,000USD0001654954-20-010891
    FY 2019Yearly · 2019-06-30SegmentAytu Bio Science7,320,000USD0001654954-20-010891
    FY 2019Yearly · 2019-06-30SegmentAytu Consumer Health0USD0001654954-20-010891
    FY 2019Yearly · 2019-06-30ProductConsumer Health Portfolio0USD0001654954-20-010891
    FY 2019Yearly · 2019-06-30ProductLicense5,776USD0001654954-20-010891
    FY 2019Yearly · 2019-06-30ProductProduct7,314,581USD0001654954-20-010891
    FY 2018Yearly · 2018-06-30GeographyRow447,000USD0001654954-19-011147
    FY 2018Yearly · 2018-06-30GeographyUnited States3,213,000USD0001654954-19-011147
    FY 2018Yearly · 2018-06-30SegmentAytu Bioscience Inc3,417,000USD0001213900-18-012209
    FY 2018Yearly · 2018-06-30SegmentAytu Womens Health243,000USD0001213900-18-012209

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.